GlassScriptPhysician profile
Monica B Manocha
NPI 1396732376
$2,626.06
in general payments reported to CMS, 2019-2025
20 companies · $471 in 2025
The $471 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $177 · 2021: $381 · 2022: $477 · 2023: $228 · 2024: $424 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $661.31 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $294.19 | 2019-2025 | |
| Sanofi Pasteur INC. | $262.24 | 2019-2025 | |
| New World Medical,INC. | $173.81 | 2021-2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Glaxosmithkline, LLC. | $151.81 | 2019-2022 | |
| Sobi, INC | $147.64 | 2019-2024 | |
| Corium, LLC | $136.51 | 2022-2024 | Azstarys |
| Alcon Vision LLC | $124.55 | 2025 | Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $99.77 | 2024-2025 | Veritas Vision System, Tecnis Iol, Catalys System |
| Rxsight INC | $94.87 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Merck Sharp & Dohme LLC | $91.87 | 2020-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sun Pharmaceutical Industries INC. | $83.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.79 | 2020-2021 | |
| Adlon Therapeutics L.P. | $53.12 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $48.11 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $45.91 | 2019 | |
| Tris Pharma INC | $21.76 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.99 | 2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $17.14 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $17.02 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Manocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.